Queen’s Canadian Cancer Trials Group receives $30M from CCS

Queen’s University’s Canadian Cancer Trials Group (CCTG) has received $30M in renewed support over five years from the Canadian Cancer Society (CCS). The funding will help CCTG to continue its cancer research, which includes between 60 and 70 clinical trials at any given time, and to continue its planned expansion of its leadership in immunotherapy. “The successful CCS grant renewal is a recognition of the exceptional caliber of our national scientific leaders, international research activities and the impact our trials have on new treatments for people with cancer,” said CCTG Director Janet Dancey. “The funding will ensure that Canadian-led trials find answers to what is most important to Canadian patients and clinicians.” Queen’s Note: Archived stories may contain dead links or be missing source links.